American regulators have approved a second drug that stimulates the immune system to attack the melanoma. This is a new cancer therapy implemented first by a scientist from Houston. The drug in question, called Keytruda (pembrolizumab) belongs to a type known as immunotherapy that has long confounded cancer experts but is finally taking its place along with surgery, radiation and chemotherapy. Drugs based on this approach have only been approved to treat melanoma, but are proving promising in clinical trials with other types of cancer.
"This is a good day for patients with melanoma and possibly for many other cancer patients," said Jim Allison, an expert in immunology at MD Anderson Cancer Center discovered a kind of brake on the immune system that prevents it attack malignant tumors and has now moved that finding a drug that releases the defender of our body system.
"That the Federal Food and Drug Administration (FDA, for its acronym in English) has approved this, says you understand that this type of drug works and want to accelerate patient access to it," said the expert. Allison The drug, known as Yervoy (ipilimumab) was adopted in 2012 Meanwhile, the drug has Keytruda in the window to an inhibitor of the immune system called programmed death receptor (PD-1) or tumor-associated target (PD-L1), which is used by cancer cells to evade our body that defend us from disease. However, the PD-1 differs identified by Allison brake. FDA said in a statement that the Keytruda be used after treatment with Yervoy. Melanoma is diagnosed at about 76,100 Americans a year, representing 5 percent of cancers diagnosed in the United States. About 10,000 people die each year from this type of cancer, according to the National Cancer Institute. - See more at: http://lavoztx.com/news/2014/sep/05/la-fda-aprueba-segundo-farmaco-innovador-contra-el/#sthash.MUPFywAU.dpuf
0 comments:
Post a Comment